Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso-occlusive pain: A randomized placebo-controlled trial in progress

Am J Hematol. 2022 Jan 1;97(1):E21-E24. doi: 10.1002/ajh.26396. Epub 2021 Nov 12.

Authors

Loretta Z Reyes^{1

2}, Janet Figueroa^{1

2}, Deborah Leake², Kirshma Khemani^{1

2}, Polly Kumari^{1

2}, Nitya Bakshi^{1

2}, Peter A Lane^{1

2}, Carlton Dampier^{1

2}, Claudia R Morris^{1

2}

Affiliations

¹ Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
² Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Administration, Intravenous
Adolescent
Adult
Anemia, Sickle Cell / complications
Anemia, Sickle Cell / drug therapy*
Arginine / administration & dosage
Arginine / adverse effects
Arginine / therapeutic use*
Child
Child, Preschool
Hospitalization
Humans
Pain / complications
Pain / drug therapy
Placebo Effect
Prospective Studies
Young Adult

Substances

Arginine

Associated data

ClinicalTrials.gov/NCT02536170

Grants and funding